Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1260219.RAVM873roZaL-eaNrlNSv3OSxDnvbZ0xLJSVwVw8QG5zY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1260219.RAVM873roZaL-eaNrlNSv3OSxDnvbZ0xLJSVwVw8QG5zY130_assertion type Assertion NP1260219.RAVM873roZaL-eaNrlNSv3OSxDnvbZ0xLJSVwVw8QG5zY130_head.
- NP1260219.RAVM873roZaL-eaNrlNSv3OSxDnvbZ0xLJSVwVw8QG5zY130_assertion description "[They also suggest that clinical trials of immunomodulatory drugs related to CTLA4 and that are already Food and Drug Administration approved as therapies for other autoimmune diseases could be considered for patients with refractory disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1260219.RAVM873roZaL-eaNrlNSv3OSxDnvbZ0xLJSVwVw8QG5zY130_provenance.
- NP1260219.RAVM873roZaL-eaNrlNSv3OSxDnvbZ0xLJSVwVw8QG5zY130_assertion evidence source_evidence_literature NP1260219.RAVM873roZaL-eaNrlNSv3OSxDnvbZ0xLJSVwVw8QG5zY130_provenance.
- NP1260219.RAVM873roZaL-eaNrlNSv3OSxDnvbZ0xLJSVwVw8QG5zY130_assertion SIO_000772 25643325 NP1260219.RAVM873roZaL-eaNrlNSv3OSxDnvbZ0xLJSVwVw8QG5zY130_provenance.
- NP1260219.RAVM873roZaL-eaNrlNSv3OSxDnvbZ0xLJSVwVw8QG5zY130_assertion wasDerivedFrom befree-2016 NP1260219.RAVM873roZaL-eaNrlNSv3OSxDnvbZ0xLJSVwVw8QG5zY130_provenance.
- NP1260219.RAVM873roZaL-eaNrlNSv3OSxDnvbZ0xLJSVwVw8QG5zY130_assertion wasGeneratedBy ECO_0000203 NP1260219.RAVM873roZaL-eaNrlNSv3OSxDnvbZ0xLJSVwVw8QG5zY130_provenance.